Traditional MedicareCoverageHigh impact
Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms
Medicare/CMS - LCD·Oncology, Pathology·Local Coverage Determination
Effective date
May 15, 2026
We identified it
Jul 28, 2026
Summary
Wellpoint Federal has issued a new Local Coverage Determination (L37810) effective 5/15/2026 establishing coverage and billing guidelines for genomic sequence analysis panels used in the treatment of solid organ neoplasms. This policy applies to both Medicare Part A and Part B claims and requires immediate review to ensure compliant billing of genomic testing services for cancer patients.
Action Required
By 5/15/2026: Billing team must obtain and review the complete LCD L37810 policy text from the CMS Medicare Coverage Database (https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37810&ver=26). Extract all covered CPT/HCPCS codes for genomic sequence analysis panels and update billing system to enforce any prior authorization requirements or medical necessity documentation rules. Providers must be notified of coverage criteria and documentation requirements for solid organ neoplasm cases. Update encounter templates and pre-authorization workflows as specified in the full policy. Failure to comply with coverage limitations and documentation requirements will result in claim denials from Wellpoint Federal.